Abstract

An aspect is to provide a prebiotic for growing a butyrate-producing bacterium. A prebiotic composition for a butyrate-producing bacterium includes alginic acid and/or a salt thereof having an average molecular weight of 10000 or less.

IPC Classes  ?

• A23L 33/10 - Modifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives
• A23L 33/135 - Bacteria or derivatives thereof, e.g. probiotics
• A61K 31/734 - Alginic acid

Abstract

The present disclosure addresses the problem of providing technology which achieves good dispersibility, in a solvent or solution, of a bacteria powder that is obtained via a spray-drying step, which achieves good yield, and in which the ratio of the number of bacteria in a resultant bacteria powder is equivalent to that of conventional products. This problem is solved by a production method for a bacteria powder comprising: a preparation step for preparing a liquid mixture which contains bacteria and an amylolysis product and which has a viscosity of not less than 75 mPa･s at 10°C; and a spray-drying step for spray-drying the liquid mixture to obtain a bacteria powder.

IPC Classes  ?

• A23L 33/135 - Bacteria or derivatives thereof, e.g. probiotics
• C12N 1/20 - BacteriaCulture media therefor

Abstract

This frozen dessert contains sugar and dietary fiber, and the average diameter of ice crystals is 40 μm or less. This method for producing a frozen dessert comprises a freezing step, an extrusion molding step, and a hardening step. In the freezing step, a raw material mix containing dietary fiber is cooled to the freezing point of the raw material mix or lower in a continuous freezer to continuously prepare a partially frozen product. In the extrusion molding step, the partially frozen product is extruded from an extrusion port to obtain an unhardened molded product. In the hardening step, the unhardened molded product is hardened to obtain a hardened product. The viscosity of the raw material mix at 5°C is 100-1500 mPa·s. The temperature for extruding the partially frozen product is -6.0°C to -3.5°C.

IPC Classes  ?

• A23G 9/14 - Continuous production
• A23G 9/34 - Frozen sweets, e.g. ice confectionery, ice-creamMixtures therefor characterised by the composition characterised by carbohydrates used, e.g. polysaccharides

Abstract

The problem addressed by the present invention is that of providing a novel method for producing a container-packaged solid food.　The solution to the problem is a method for producing a container-packaged solid food comprising a solid edible portion and a packaging portion, said method comprising a packaging portion formation step for forming the packaging portion by packaging the solid edible portion in vacuum or deaerated packaging, the solid edible portion being produced by a method including: a filling step for filling a mould with a powder containing a lipid and a carbohydrate; and a wet heat treatment step for performing a wet heat treatment under conditions of a relative humidity of 10% or more and a temperature of 80°C or more.

IPC Classes  ?

• A23L 5/00 - Preparation or treatment of foods or foodstuffs, in generalFood or foodstuffs obtained therebyMaterials therefor
• A23C 9/18 - Milk in dried and compressed or semi-solid form
• A23P 10/28 - TablettingMaking food bars by compression of a dry powdered mixture
• A23P 30/00 - Shaping or working of foodstuffs characterised by the process or apparatus

Abstract

This fermented composition comprises whey protein, a bacterium of the genus Bifidobacterium, a lactic acid bacterium, and acetic acid, wherein the content of acetic acid is 250 mg/100 g or more with respect to the total mass of the fermented composition. This method for producing a fermented composition involves: adding a bacterium of the genus Bifidobacterium and a lactic acid bacterium to a raw material composition containing whey protein; and fermenting same until the acetic acid content reaches at least 250 mg/100 g with respect to the total mass of the raw material composition, the bacterium of the genus Bifidobacterium, and the lactic acid bacterium.

IPC Classes  ?

• A23C 9/12 - Fermented milk preparationsTreatment using microorganisms or enzymes
• A23C 9/13 - Fermented milk preparationsTreatment using microorganisms or enzymes using additives
• A23C 9/127 - Fermented milk preparationsTreatment using microorganisms or enzymes using microorganisms of the genus lactobacteriaceae and other microorganisms or enzymes, e.g. kefir, koumiss
• A23C 21/00 - WheyWhey preparations
• A23L 2/38 - Other non-alcoholic beverages
• A23L 2/52 - Adding ingredients
• A23L 2/66 - Proteins
• C12J 1/06 - VinegarPreparation or purification thereof from milk

Abstract

The present invention addresses the problem of providing a novel functionality of Bifidobacterium longum subsp. infantis M-63 strain (NITE BP-02623).　In a composition to be ingested by healthy newborns who are born in full term or healthy infants, one or more components selected from cells of Bifidobacterium longum subsp. infantis M-63 strain (NITE BP-02623), a culture of the bacterium, and a treated product of the bacterium are contained as active ingredients. The problem is solved by subjecting the composition to an application for reducing the number of bacteria belonging to the family Enterobacteriaceae in the intestinal flora, an application for promoting the proliferation of bacteria belonging to the genus Bifidobacterium, or an anti-inflammatory application.

IPC Classes  ?

• A23L 33/135 - Bacteria or derivatives thereof, e.g. probiotics
• A23L 2/52 - Adding ingredients
• A23L 33/125 - Modifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives containing carbohydrate syrupsModifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives containing sugarsModifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives containing sugar alcoholsModifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives containing starch hydrolysates
• A61K 35/745 - Bifidobacteria
• A61P 1/04 - Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
• C12N 1/20 - BacteriaCulture media therefor
• C12Q 1/689 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria

Abstract

This method for producing a frozen dessert has a freezing step in which a raw material liquid containing live bifidobacteria is frozen to obtain a partially frozen product. In order to suppress death of bifidobacteria, the freezing temperature in the freezing step is set to be lower than or equal to the freezing point of the raw material liquid, and the absolute value of the difference between the freezing point of the raw material liquid and the freezing temperature is set to be less than or equal to 2.0°C.

IPC Classes  ?

• A23G 9/36 - Frozen sweets, e.g. ice confectionery, ice-creamMixtures therefor characterised by the composition containing microorganisms or enzymesFrozen sweets, e.g. ice confectionery, ice-creamMixtures therefor characterised by the composition containing paramedical or dietetical agents, e.g. vitamins
• A23L 33/135 - Bacteria or derivatives thereof, e.g. probiotics

Goods & Services

Chemicals containing lactobacillus; bifidobacteria for use in the manufacture of food and beverages; lactobacillus for use in the manufacture of food and beverages; bifidobacteria strains for use in the manufacture of food and beverages; lactobacillus strains for use in the manufacture of food and beverages; powdered bacteria for use in the manufacture of animal feed; bacterial strains for use in the manufacture of animal feed; plant growth regulating preparations containing lactobacillus; fertilizers containing lactobacillus; artificial sweeteners containing lactobacillus for industrial purposes; flour and starch containing lactobacillus for industrial purposes. Pharmaceutical preparations and substances containing lactobacillus; dietetic food preparations containing lactobacillus; nutritional additives containing lactobacillus for medical use; nutritional supplement containing lactobacillus for medical use; lactobacillus for medical use; lactobacillus strains for medical use; lacteal flour for babies containing lactobacillus; dietary supplements for human containing lactobacillus; food containing lactobacillus for people with chewing and swallowing disorders; dietetic foods containing lactobacillus adapted for medical purposes; dietetic beverages containing lactobacillus adapted for medical purposes; beverages for babies containing lactobacillus; food for babies containing lactobacillus; dietary supplements containing lactobacillus for animals. Edible oils and fats containing lactobacillus; milk products containing lactobacillus; frozen fruits containing lactobacillus; processed vegetables and fruits containing lactobacillus; fried tofu pieces [Abura-age] containing lactobacillus; freeze-dried tofu pieces [Kohri-dofu] containing lactobacillus; jelly made from devils' tongue root [Konnyaku] containing lactobacillus; soya milk containing lactobacillus; tofu containing lactobacillus; fermented soybeans [Natto] containing lactobacillus; pre-cooked curry stew, stew and soup mixes all containing lactobacillus; protein foodstuffs containing lactobacillus for human consumption; kefir spawn containing lactobacillus. Tea containing lactobacillus; coffee containing lactobacillus; cocoa containing lactobacillus; sweets, confectionery and snacks containing lactobacillus; bread containing lactobacillus; sandwiches containing lactobacillus; steamed buns stuffed with minced meat [Chuka-manjuh] containing lactobacillus; hamburger sandwiches containing lactobacillus; fresh pizzas containing lactobacillus; hot dog sandwiches containing lactobacillus; meat pies containing lactobacillus; ice cream mixes containing lactobacillus; sherbet mixes containing lactobacillus; soft serve ice cream mixes containing lactobacillus; Chinese stuffed dumplings containing lactobacillus; Chinese steamed dumplings containing lactobacillus; sushi containing lactobacillus; fried balls of batter mix with small pieces of octopus [Takoyaki] containing lactobacillus; boxed lunches consisting of rice, with added meat, fish or vegetables containing lactobacillus; ravioli containing lactobacillus; yogurt culture containing lactobacillus; lactobacillus bacteria for household use; lactic acid fermentation culture for making foods and beverages for household use; yeast powder containing lactobacillus; fermented malted rice [Koji] containing lactobacillus; yeast containing lactobacillus; baking powder containing lactobacillus; instant confectionery mixes containing lactobacillus. Wreaths of natural flowers for ceremonies or funerals; fishing baits; unprocessed hops; edible aquatic animals, live; edible seaweeds, unprocessed; fresh vegetables; sugar crops; fresh fruit; malt; foxtail millet, unprocessed; proso millet, unprocessed; sesame, unprocessed; buckwheat, unprocessed; corn [unprocessed grain]; Japanese barnyard millet, unprocessed; wheat, barley and oats, unprocessed; unprocessed rice; sorghum; protein-enriched feed for animal consumption; milks for pets; pet food; biscuit for pets; animal foodstuffs; seeds and bulbs; trees; grasses [plants]; turf, natural; dried flowers; seedlings; saplings; flowers [natural]; pasture grass; natural bonsai trees; live mammals, fish [not for food], birds and insects; silkworm eggs; cocoons for silkworm breeding; eggs for hatching; Urushi tree seeds; rough cork; palm fronds. Beers containing lactobacillus; soft drinks containing lactobacillus; fruit drinks containing lactobacillus; vegetable juices [beverages] containing lactobacillus; extracts of hops for making beer containing lactobacillus; whey beverages containing lactobacillus.

Abstract

The present invention provides an oral composition for intestinal delivery comprising one or more selected from the bacterium Bifidobacterium longum subspecies infantis MCC2042 (NITE PB-03068), a cultured product of this bacterium, and a treated product of this bacterium. The oral composition for intestinal delivery may demonstrate a bacterial survival rate of at least 80% after treatment for 60 minutes in a liquid with a pH of 3.0 at 37°C.

IPC Classes  ?

• A23L 33/135 - Bacteria or derivatives thereof, e.g. probiotics
• A23C 9/00 - Milk preparationsMilk powder or milk powder preparations
• A23C 9/123 - Fermented milk preparationsTreatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceaeYoghurt
• A61K 9/14 - Particulate form, e.g. powders
• A61K 31/702 - Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
• A61K 35/745 - Bifidobacteria
• A61K 47/38 - CelluloseDerivatives thereof
• A61P 1/00 - Drugs for disorders of the alimentary tract or the digestive system
• A61P 43/00 - Drugs for specific purposes, not provided for in groups
• C12N 1/20 - BacteriaCulture media therefor

Abstract

A cheese according to one embodiment comprises natural cheese, unprocessed starch, and processed starch, wherein the processed starch includes acetylated starch. A method for producing a cheese according to one embodiment comprises: a step for obtaining a heated and emulsified product by heating and emulsifying a raw material composition which contains natural cheese, unprocessed starch, and processed starch and in which the processed starch includes acetylated starch; and a step for obtaining a cooled and solidified product by cooling the heated and emulsified product.

IPC Classes  ?

• A23C 19/082 - Adding substances to the curd before or during meltingMelting salts

Abstract

The present invention addresses the problem of providing: an oxygen-tolerant bacterium of the genus Bifidobacterium, which can be cultured even under aerobic conditions; a culture method and a screening method for the bacterium; a composition containing oxygen-tolerant bacterium of the genus Bifidobacterium; and a method for producing the composition.　The present invention which can solve the problem is a method for culturing a bacterium of the genus Bifidobacterium, wherein the bacterium has any one gene selected from the below-mentioned genes (1) to (7). The method includes culturing the bacterium under aerobic conditions. (1) A gene which comprises a nucleotide sequence represented by SEQ ID NO: 1 or 2. (2) A gene which has 90% or higher identity with the nucleotide sequence represented by SEQ ID NO: 1 or 2. (3) A gene which comprises a nucleotide sequence having a structure such that one to several nucleotides are deleted, substituted, or added in the nucleotide sequence represented by SEQ ID NO: 1 or 2. (4) A gene which comprises a nucleotide sequence of a DNA fragment that is capable of hybridizing, under stringent conditions, with a DNA fragment comprising a sequence complementary to the nucleotide sequence represented by SEQ ID NO: 1 or 2. (5) A gene which comprises a degenerate isomer of the nucleotide sequence represented by SEQ ID NO: 1 or 2. (6) A gene which encodes a protein comprising an amino acid sequence represented by SEQ ID NO: 3 or 4. (7) A gene which encodes a protein comprising an amino acid sequence having a structure such that one to several amino acid residues are deleted, substituted, or added in the amino acid sequence represented by SEQ ID NO: 3 or 4.

IPC Classes  ?

• C12N 1/20 - BacteriaCulture media therefor
• A23C 9/123 - Fermented milk preparationsTreatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceaeYoghurt
• A23L 33/135 - Bacteria or derivatives thereof, e.g. probiotics
• C12N 1/21 - BacteriaCulture media therefor modified by introduction of foreign genetic material
• C12N 15/31 - Genes encoding microbial proteins, e.g. enterotoxins
• C12P 1/04 - Preparation of compounds or compositions, not provided for in groups , by using microorganisms or enzymesGeneral processes for the preparation of compounds or compositions by using microorganisms or enzymes by using bacteria
• C12Q 1/04 - Determining presence or kind of microorganismUse of selective media for testing antibiotics or bacteriocidesCompositions containing a chemical indicator therefor
• C12Q 1/689 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria

Abstract

The present invention addresses the problem of providing a novel technique for producing coffee from which an excellent coffee-derived flavor can be felt even when a milk-derived component is added to the coffee.　The present invention, which solves the above problem, is a method for producing coffee, the method comprising: an aroma condensate production step in which roasted and milled coffee beans are brought into contact with steam to produce steam that contains aroma components derived from the coffee beans, and the steam is cooled to 45°C or lower to produce an aroma condensate; and a mixing step in which the aroma condensate is mixed with a coffee extract that is produced by bringing roasted and milled coffee beans into contact with water, thereby producing the coffee.

IPC Classes  ?

• A23F 5/10 - Treating roasted coffeePreparations produced thereby
• A23F 5/24 - Extraction of coffeeCoffee extractsMaking instant coffee
• A23F 5/48 - Isolation of coffee flavour or coffee oil

Abstract

A technique for promoting the assimilation of an oligosaccharide such as an HMO by an intestinal bacterium, especially a bifidobacterial strain, is provided. As a first aspect, a composition for promoting the assimilation of an oligosaccharide containing a tocopherol is provided. As a second aspect, a nutritional composition (excluding breast milk) containing an oligosaccharide and a tocopherol is provided. The tocopherol in the aspects contains one, two or more kinds selected from the group consisting of β-tocopherol, γ-tocopherol and δ-tocopherol. The oligosaccharide in the aspects is preferably a human milk oligosaccharides. The mass ratio of the δ-tocopherol content to the β-tocopherol content (δ/β) in the aspects is preferably 5 or more, and the mass ratio of the γ-tocopherol content to the δ-tocopherol content (γ/δ) is preferably 8.8 or less.

IPC Classes  ?

• A61K 31/355 - Tocopherols, e.g. vitamin E
• A61K 31/702 - Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
• A61K 35/00 - Medicinal preparations containing materials or reaction products thereof with undetermined constitution
• A61K 35/20 - MilkWheyColostrum
• A61K 35/745 - Bifidobacteria
• A61P 1/14 - Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents

Abstract

This pasteurized milk beverage which contains milk protein and calcium, which has a pH at 25°C of 5.0 or less, in which the milk protein contains whey protein and the whey protein content is 40 mass% or more with respect to the total mass of the proteins contained in the pasteurized milk beverage, and which contains a phosphate and an acidified milk stabilizer has good solution stability despite containing milk protein and calcium and having a low pH.

IPC Classes  ?

• A23C 9/152 - Milk preparationsMilk powder or milk powder preparations containing additives
• A23C 9/13 - Fermented milk preparationsTreatment using microorganisms or enzymes using additives

Abstract

This bacterium is Bifidobacterium bifidum MCC2085 (NITE BP-03881). This composition contains the bacterium. The composition is a food or beverage composition. The food or beverage composition is a probiotic composition or a nutritional composition. The method for producing a composition includes a step for mixing the bacterium with a raw material other than the bacterium.

IPC Classes  ?

• A23L 33/135 - Bacteria or derivatives thereof, e.g. probiotics
• A23C 9/00 - Milk preparationsMilk powder or milk powder preparations
• A23C 9/127 - Fermented milk preparationsTreatment using microorganisms or enzymes using microorganisms of the genus lactobacteriaceae and other microorganisms or enzymes, e.g. kefir, koumiss
• A23L 2/52 - Adding ingredients
• A23L 33/10 - Modifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives
• A23L 33/125 - Modifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives containing carbohydrate syrupsModifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives containing sugarsModifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives containing sugar alcoholsModifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives containing starch hydrolysates
• A61K 35/745 - Bifidobacteria
• A61P 1/00 - Drugs for disorders of the alimentary tract or the digestive system
• A61P 1/04 - Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
• A61P 1/10 - Laxatives
• A61P 1/12 - Antidiarrhoeals
• A61P 1/14 - Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
• A61P 25/20 - HypnoticsSedatives
• A61P 25/22 - Anxiolytics
• A61P 25/24 - Antidepressants
• C12N 1/20 - BacteriaCulture media therefor
• C12N 15/09 - Recombinant DNA-technology

Abstract

This serotonin production promoting composition contains one or more types selected from bacteria that are Bifidobacterium bifidum MCC2085 (NITE BP-03881), cultures of the bacteria, and treated products of the bacteria. The serotonin production promoting composition contains one or more types selected from bacteria that are Bifidobacterium longum subspecies infantis M-63 (NITE BP-02623), cultures of the bacteria, and treated products of the bacteria.

IPC Classes  ?

• A23L 33/135 - Bacteria or derivatives thereof, e.g. probiotics
• A23C 9/00 - Milk preparationsMilk powder or milk powder preparations
• A61K 35/745 - Bifidobacteria
• A61P 1/00 - Drugs for disorders of the alimentary tract or the digestive system
• A61P 1/10 - Laxatives
• A61P 1/12 - Antidiarrhoeals
• A61P 25/20 - HypnoticsSedatives
• A61P 25/22 - Anxiolytics
• A61P 25/24 - Antidepressants
• C12N 1/20 - BacteriaCulture media therefor
• C12N 15/09 - Recombinant DNA-technology

Abstract

This fermented food, obtained by fermenting a raw material composition comprising bifidobacteria, Lactococcus bacteria, and an iron-containing compound, exhibits excellent bifidobacteria survival.

IPC Classes  ?

• A23L 5/00 - Preparation or treatment of foods or foodstuffs, in generalFood or foodstuffs obtained therebyMaterials therefor
• A23L 33/135 - Bacteria or derivatives thereof, e.g. probiotics

Abstract

The present invention addresses the problem of providing bacteria which belong to Lactobacillus helveticus and which have an excellent IFN production inducing effect. Provided are bacteria that activate a plasmacytoid dendritic cells (pDC) and/or a myeloid dendritic cells (mDC) and that are capable of inducing I-type IFN production, said bacteria being classified as Lactobacillus helveticus and inducing I-type IFN production which is at least 1.5 times that of Lactobacillus helveticus SBT2171 (accession number: Ferm BP-5445).

IPC Classes  ?

• C12N 1/20 - BacteriaCulture media therefor
• A23L 33/135 - Bacteria or derivatives thereof, e.g. probiotics
• A61K 35/747 - Lactobacilli, e.g. L. acidophilus or L. brevis
• A61P 19/00 - Drugs for skeletal disorders
• A61P 19/08 - Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
• A61P 31/12 - Antivirals
• A61P 35/00 - Antineoplastic agents
• A61P 37/02 - Immunomodulators
• A61P 37/04 - Immunostimulants

Abstract

The present invention provides a composition comprising Bifidobacterium, preferably Bifidobacterium breve or Bifidobacterium longum sub. infantis. The composition is used for reducing PLIN4 gene expression and/or for preventing, improving, and/or treating diseases caused by PLIN4 overexpression and/or lipid droplets accumulation.

IPC Classes  ?

• A61K 35/745 - Bifidobacteria
• A61P 25/16 - Anti-Parkinson drugs
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• A61P 35/00 - Antineoplastic agents

Abstract

The present invention addresses the problem of providing a novel method for producing a solid food. The solution to the problem is a method for producing a solid food, the method comprising: a filling step in which a container is filled with a powder including lipid and sugar; and a moist-heat treatment step in which, after the filling step, the powder is subjected to a moist-heat treatment under conditions of a relative humidity of 10% or more and a temperature of 80°C or more.

IPC Classes  ?

• A23L 5/10 - General methods of cooking foods, e.g. by roasting or frying
• A23C 9/18 - Milk in dried and compressed or semi-solid form
• A23L 5/00 - Preparation or treatment of foods or foodstuffs, in generalFood or foodstuffs obtained therebyMaterials therefor

Abstract

The present invention addresses the problem of providing a technology for anti-obesity. This problem is solved by an anti-obesity composition containing a peptide comprising Leu-Asp-Gln-Trp (SEQ ID NO: 1), an anti-obesity composition containing a peptide comprising Leu-Lys-Pro-Thr-Pro-Glu-Gly-Asp-Leu-Glu-Ile-Leu (SEQ ID NO: 2), or an anti-obesity composition containing a peptide comprising Leu-Asp-Gln-Trp (SEQ ID NO: 1) and a peptide comprising Leu-Lys-Pro-Thr-Pro-Glu-Gly-Asp-Leu-Glu-Ile-Leu (SEQ ID NO: 2).

IPC Classes  ?

• A23L 33/18 - PeptidesProtein hydrolysates
• A61K 38/07 - Tetrapeptides
• A61K 38/10 - Peptides having 12 to 20 amino acids
• A61P 3/04 - AnorexiantsAntiobesity agents

Abstract

The present invention addresses the problem of providing a novel protein beverage in which sedimentation of heat-sterilized separated soybean protein is suppressed, and a method for producing the same.　The present invention, which solves the above problem, is a protein-containing beverage which comprises separated soybean protein and tofu and in which the total mass of protein relative to the total mass of the protein-containing beverage is greater than 6 mass%.

IPC Classes  ?

• A23L 2/66 - Proteins
• A23L 2/38 - Other non-alcoholic beverages
• A23L 11/60 - Drinks from legumes, e.g. lupine drinks

Goods & Services

Chemicals; protein (raw material); oligosaccharides; peptide (raw material); lactulose (raw material); bifidobacteria for use in the manufacture of food and beverages; lactobacillus for use in the manufacture of food and beverages; bifidobacteria strains for use in the manufacture of food and beverages; lactobacillus strains for use in the manufacture of food and beverages; microorganisums (bacteria, bacteria powder) for use in the manufacture of food and beverages; cultures of microorganisms for use in the manufacture of food and beverages; bacteria for use in food manufacture; bacteria strain for use in food manufacture; powdered bacteria for use in the manufacture of animal feed; bacterial strains for use in the manufacture of animal feed; cultures of microorganisms, other than for medical and veterinary use; plant growth regulating preparations; fertilizers; artificial sweeteners for industrial purposes; flour and starch for industrial purposes; biological preparations for use in industry and science; glue and adhesives for industrial purposes. Pharmaceutical preparations and substances; reagent paper for medical purposes; oiled paper for medical purposes; adhesive tapes for medical purposes; drug delivery agents in the form of edible wafers for wrapping powdered pharmaceuticals; gauze for dressings; empty capsules for pharmaceuticals; eyepatches for medical purposes; ear bandages; menstruation bandages; sanitary tampons; sanitary napkins; sanitary panties; absorbent cotton; adhesive plasters; bandages for dressings; liquid bandages; breast-nursing pads; cotton swabs for medical use; dental materials; diapers; diaper covers; fly catching paper; mothproofing paper; lacteal flour for babies; lacteal flour for infants; lacteal flour being nutritional supplements for children; dietary supplements for human; dietetic beverages adapted for medical purposes; dietetic foods adapted for medical purposes; beverages for babies; beverages for infants; nutritional supplement beverages for children; food for babies; food for infants; food supplements for children; dietary supplements for animals; semen for artificial insemination; dietary fiber; cultures of microorganisms for medical or veterinary use; powdered bacteria for medical use; bacteria strain for medical use. Fruit-based, vegetable-based, bean-based or nut-based snacks; edible oils and fats; milk products; milk; milk beverages; lactic acid bacteria drinks; cream; whipped cream; cheese; butter; powdered milk; condensed milk; yoghurt; yoghurt drinks; meat; eggs; seafood, not live; frozen vegetables; frozen fruits; processed meat products; processed seafood products; processed vegetables and fruits; jellies for food, other than confectionery; fried tofu pieces [abura-age]; freeze-dried tofu pieces [kohri-dofu]; jelly made from devils' tongue root [konnyaku]; soya milk; tofu; fermented soybeans [natto]; processed eggs; pre-cooked curry stew, stew and soup mixes; dried flakes of laver for sprinkling on rice in hot water [ochazuke-nori]; dried flakes of fish, meat, vegetables or seaweed [furi-kake]; side-dish made of fermented soybean [name-mono]; preserved pulses; protein milk; milk ferments for culinary purposes; dried milk for food. Binding agents for ice cream; meat tenderizers for culinary purposes; preparations for stiffening whipped cream; aromatic preparations for food; tea; coffee; cocoa; ice; sweets, confectionery and snacks made predominantly from rice, cereal, muesli and corn; ice cream; ice pops; sorbets; pudding; ice cream cones; jellies [confectionery]; bread; sandwiches; steamed buns stuffed with minced meat [chuka-manjuh]; hamburger sandwiches; fresh pizzas; hot dog sandwiches; meat pies; seasonings; spices; ice cream mixes; sherbet mixes; soft serve ice cream mixes; unroasted coffee; processed cereals; processed grains; chocolate spreads; Chinese stuffed dumplings; Chinese steamed dumplings; sushi; fried balls of batter mix with small pieces of octopus [takoyaki]; boxed lunches consisting of rice, with added meat, fish or vegetables; ravioli; yeast powder; fermented malted rice [koji]; yeast; baking powder; instant confectionery mixes; pasta sauce; gluten for food; flour; by-product of rice for food [sake lees]; husked rice; husked oats; husked barley; edible paper; confectionery containing lactulose. Beers; soft drinks; fruit drinks; vegetable juices [beverages]; extracts of hops for making beer; whey beverages; non-alcoholic essences for making beverages; soya-based beverages, other than milk substitutes.

Goods & Services

Chemicals; protein (raw material); oligosaccharides; peptide (raw material); lactulose (raw material); bifidobacteria for use in the manufacture of food and beverages; lactobacillus for use in the manufacture of food and beverages; bifidobacteria strains for use in the manufacture of food and beverages; lactobacillus strains for use in the manufacture of food and beverages; microorganisums (bacteria, bacteria powder) for use in the manufacture of food and beverages; cultures of microorganisms for use in the manufacture of food and beverages; bacteria for use in food manufacture; bacteria strain for use in food manufacture; powdered bacteria for use in the manufacture of animal feed; bacterial strains for use in the manufacture of animal feed; cultures of microorganisms, other than for medical and veterinary use; plant growth regulating preparations; fertilizers; artificial sweeteners for industrial purposes; flour and starch for industrial purposes; biological preparations for use in industry and science; glue and adhesives for industrial purposes. Pharmaceutical preparations and substances; reagent paper for medical purposes; oiled paper for medical purposes; adhesive tapes for medical purposes; drug delivery agents in the form of edible wafers for wrapping powdered pharmaceuticals; gauze for dressings; empty capsules for pharmaceuticals; eyepatches for medical purposes; ear bandages; menstruation bandages; sanitary tampons; sanitary napkins; sanitary panties; absorbent cotton; adhesive plasters; bandages for dressings; liquid bandages; breast-nursing pads; cotton swabs for medical use; dental materials; diapers; diaper covers; fly catching paper; mothproofing paper; lacteal flour for babies; lacteal flour for infants; lacteal flour being nutritional supplements for children; dietary supplements for human; dietetic beverages adapted for medical purposes; dietetic foods adapted for medical purposes; beverages for babies; beverages for infants; nutritional supplement beverages for children; food for babies; food for infants; food supplements for children; dietary supplements for animals; semen for artificial insemination; dietary fiber; cultures of microorganisms for medical or veterinary use; powdered bacteria for medical use; bacteria strain for medical use. Fruit-based, vegetable-based, bean-based or nut-based snacks; edible oils and fats; milk products; milk; milk beverages; lactic acid bacteria drinks; cream; whipped cream; cheese; butter; powdered milk; condensed milk; yoghurt; yoghurt drinks; meat; eggs; seafood, not live; frozen vegetables; frozen fruits; processed meat products; processed seafood products; processed vegetables and fruits; jellies for food, other than confectionery; fried tofu pieces [abura-age]; freeze-dried tofu pieces [kohri-dofu]; jelly made from devils' tongue root [konnyaku]; soya milk; tofu; fermented soybeans [natto]; processed eggs; pre-cooked curry stew, stew and soup mixes; dried flakes of laver for sprinkling on rice in hot water [ochazuke-nori]; dried flakes of fish, meat, vegetables or seaweed [furi-kake]; side-dish made of fermented soybean [name-mono]; preserved pulses; protein milk; milk ferments for culinary purposes; dried milk for food. Binding agents for ice cream; meat tenderizers for culinary purposes; preparations for stiffening whipped cream; aromatic preparations for food; tea; coffee; cocoa; ice; sweets, confectionery and snacks made predominantly from rice, cereal, muesli and corn; ice cream; ice pops; sorbets; pudding; ice cream cones; jellies [confectionery]; bread; sandwiches; steamed buns stuffed with minced meat [chuka-manjuh]; hamburger sandwiches; fresh pizzas; hot dog sandwiches; meat pies; seasonings; spices; ice cream mixes; sherbet mixes; soft serve ice cream mixes; unroasted coffee; processed cereals; processed grains; chocolate spreads; Chinese stuffed dumplings; Chinese steamed dumplings; sushi; fried balls of batter mix with small pieces of octopus [takoyaki]; boxed lunches consisting of rice, with added meat, fish or vegetables; ravioli; yeast powder; fermented malted rice [koji]; yeast; baking powder; instant confectionery mixes; pasta sauce; gluten for food; flour; by-product of rice for food [sake lees]; husked rice; husked oats; husked barley; edible paper; confectionery containing lactulose. Beers; soft drinks; fruit drinks; vegetable juices [beverages]; extracts of hops for making beer; whey beverages; non-alcoholic essences for making beverages; soya-based beverages, other than milk substitutes.

Abstract

The present invention addresses the problem of providing: a composition that can be applied to a specific use such as a composition for promoting the production of aromatic lactic acid compounds or a composition for obtaining effects based on promoting the production of aromatic lactic acid compounds. The foregoing problem is solved by a composition containing: a nucleic acid metabolite such as hypoxanthine; and Bifidobacterium bacteria such as Bifidobacterium breve.

IPC Classes  ?

• C12N 1/20 - BacteriaCulture media therefor
• C12P 7/42 - Hydroxy carboxylic acids
• C12P 17/12 - Nitrogen as only ring hetero atom containing a six-membered hetero ring

Abstract

The present invention addresses the problem of providing a new functionality of Bifidobacterium longum subsp. infantis M-63 (NITE BP-02623). To a composition to be administered to healthy newborns or infants born in full term, one or more selected from Bifidobacterium longum subsp. infantis M-63 (NITE BP-02623) cells, a culture of the bacterium and a treated product of the bacterium are added as an active ingredient. This composition is used to promote the establishment of a bacterium belonging to the genus Bifidobacterium in the intestinal microflora, to promote maturation of intestinal tract function, to inhibit regurgitation of milk, or to regulate immune function.

IPC Classes  ?

• A23L 33/135 - Bacteria or derivatives thereof, e.g. probiotics
• A61K 35/745 - Bifidobacteria
• A61P 1/00 - Drugs for disorders of the alimentary tract or the digestive system
• A61P 37/02 - Immunomodulators

Abstract

A peptide which can be easily taken on a daily basis and which has few side effects and has various actions and a composition containing the peptide as an active ingredient are provided. A peptide having the amino acid sequence of (a) or (b) below is provided. (a) The amino acid sequence of SEQ ID NO: 1 (Asn-Leu-Pro-Pro-Leu-Thr). (b) An amino acid sequence in which one or several amino acids are substituted, deleted or added in the amino acid sequence of SEQ ID NO: 1. Moreover, a composition containing the peptide as an active ingredient is also provided.

IPC Classes  ?

• C07K 7/06 - Linear peptides containing only normal peptide links having 5 to 11 amino acids
• A61K 38/00 - Medicinal preparations containing peptides
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Abstract

The present invention addresses the problem of providing: a coffee containing a milk-derived ingredient and providing sensation of typical coffee's aroma and flavor; and a production method for the coffee.　This production method is for a coffee containing a milk-derived ingredient, the method comprising: an aroma condensate obtaining step for bringing roasted and ground coffee beans into contact with water vapor, and cooling the obtained water vapor containing aroma ingredients derived from the coffee beans to obtain an aroma condensate; a coffee extract-obtaining step for bringing the roasted and ground coffee beans that have been subjected to the aroma condensate obtaining step into contact with water to obtain a coffee extract; and a mixing step for mixing the aroma condensate, the coffee extract, and a milk-derived ingredient together to obtain the coffee containing the milk-derived ingredient, wherein in the aroma condensate obtaining step, the aroma condensate is obtained such that the percentage of the mass of the aroma condensate with respect to the mass of the roasted and ground coffee beans is more than 5 mass% but less than 30 mass%.

IPC Classes  ?

• A23F 5/24 - Extraction of coffeeCoffee extractsMaking instant coffee
• A23F 5/48 - Isolation of coffee flavour or coffee oil

Abstract

The present invention addresses the problem of providing a food-applicable antioxidant peptide and an antioxidant composition containing same. The present invention provides a peptide comprising the amino acid sequence of Gln-Pro-Glu-Val-Met and an antioxidant composition containing said peptide.

IPC Classes  ?

• A61P 39/06 - Free radical scavengers or antioxidants
• C12P 21/06 - Preparation of peptides or proteins produced by the hydrolysis of a peptide bond, e.g. hydrolysate products
• A23L 33/18 - PeptidesProtein hydrolysates
• A61K 35/20 - MilkWheyColostrum
• A61K 38/08 - Peptides having 5 to 11 amino acids
• C07K 7/06 - Linear peptides containing only normal peptide links having 5 to 11 amino acids

Abstract

The present invention addresses the problem of providing a fermentation composition having new nutritional properties or palatability.　Provided is a fermentation composition obtained by fermenting a milk raw material containing a whey raw material, the fermentation composition containing lactic acid and acetic acid, wherein the ratio of the mass of the acetic acid to the mass of the lactic acid is 0.4 or more.

IPC Classes  ?

• A23C 9/127 - Fermented milk preparationsTreatment using microorganisms or enzymes using microorganisms of the genus lactobacteriaceae and other microorganisms or enzymes, e.g. kefir, koumiss
• A23C 21/02 - WheyWhey preparations containing, or treated with, microorganisms or enzymes

Abstract

The present invention addresses the problem of providing technology for heightening a small intestinal absorption property of a peptide having physiological functionality. This problem is solved via a composition containing a peptide composed of amino acid sequence (a), and one or two or more selected from the group consisting of peptides composed of amino acid sequence (b) or (c). Preferably, said one or two or more peptides selected from the group consisting of peptides composed of amino acid sequence (b) or (c) include one or two or more selected from the group consisting of peptides composed of amino acid sequences (d)-(f). (a) Val-Pro (b) Xaa-Xaa-Val-Pro (c) Val-Pro-Xaa (d) Leu-Pro-Val-Pro (e) Val-Pro-Asn (f) Val-Pro-Gln

IPC Classes  ?

• A61K 38/05 - Dipeptides
• A23C 9/12 - Fermented milk preparationsTreatment using microorganisms or enzymes
• A23L 33/18 - PeptidesProtein hydrolysates
• A61K 9/14 - Particulate form, e.g. powders
• A61K 47/18 - AminesAmidesUreasQuaternary ammonium compoundsAmino acidsOligopeptides having up to five amino acids
• A61P 3/04 - AnorexiantsAntiobesity agents
• A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
• A61P 9/14 - VasoprotectivesAntihaemorrhoidalsDrugs for varicose therapyCapillary stabilisers
• A61P 43/00 - Drugs for specific purposes, not provided for in groups
• C07K 5/08 - Tripeptides
• C07K 5/10 - Tetrapeptides

Abstract

The present invention addresses the problem of providing a feature for promoting utilization of an oligosaccharide having a lacto-N-neotetraose skeleton in Bifidobacterium breve. The present invention provides a composition for promoting utilization of an oligosaccharide having a lacto-N-neotetraose skeleton in Bifidobacterium breve, the composition containing one or more saccharides selected from monosaccharides and disaccharides.

IPC Classes  ?

• A23L 33/125 - Modifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives containing carbohydrate syrupsModifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives containing sugarsModifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives containing sugar alcoholsModifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives containing starch hydrolysates
• C12N 1/38 - Chemical stimulation of growth or activity by addition of chemical compounds which are not essential growth factorsStimulation of growth by removal of a chemical compound
• C12R 1/01 - Bacteria or actinomycetales

Abstract

An object is to provide a prebiotic which efficiently proliferates a butyrate-producing bacterium. An oligosaccharide which is composed of β-D-mannuronic acid and/or α-L-guluronic acid and which has an unsaturated form of β-D-mannuronic acid residue or α-L-guluronic acid residue at the non-reducing end or a salt thereof is used as an active ingredient of a prebiotic composition for a butyrate-producing bacterium. The oligosaccharide can be produced by causing an alginate lyase to act on alginic acid and/or a salt thereof or a hydrolysate thereof and thus obtaining a degradation product of alginic acid.

IPC Classes  ?

• A61K 31/702 - Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
• C12P 19/04 - Polysaccharides, i.e. compounds containing more than five saccharide radicals attached to each other by glycosidic bonds
• A23L 33/125 - Modifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives containing carbohydrate syrupsModifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives containing sugarsModifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives containing sugar alcoholsModifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives containing starch hydrolysates

Abstract

Provided is a beverage that contains Lacticaseibacillus paracasei bacteria and non-milkfat solid matter, wherein the non-milkfat solid matter constitutes less than 8.0 mass% of the total mass of the beverage.

IPC Classes  ?

• A23C 9/123 - Fermented milk preparationsTreatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceaeYoghurt
• A23C 9/13 - Fermented milk preparationsTreatment using microorganisms or enzymes using additives
• A23L 2/52 - Adding ingredients
• A23L 2/68 - Acidifying substances
• C12R 1/225 - Lactobacillus

Abstract

Provided is fermented milk that contains Lacticaseibacillus paracasei bacteria and milk fat, wherein the milk fat constitutes at most 2.0 mass% of the total mass of the fermented milk.

IPC Classes  ?

• A23C 9/123 - Fermented milk preparationsTreatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceaeYoghurt
• A23C 9/13 - Fermented milk preparationsTreatment using microorganisms or enzymes using additives
• C12N 1/20 - BacteriaCulture media therefor
• C12R 1/225 - Lactobacillus

Abstract

This antiepileptic composition contains one of or both of a bacterium of the genus Bifidobacterium and a culture thereof. The bacterium of the genus Bifidobacterium may be Bifidobacterium breve. The bacterium of the genus Bifidobacterium may be an MCC1274 strain (FERM BP-11175) of Bifidobacterium breve. The antiepileptic composition may contain one of or both of the bacterium of the genus Bifidobacterium and a culture thereof in an amount of 1×106to 1×1012 CFU/g.

IPC Classes  ?

• A61K 35/745 - Bifidobacteria
• A23L 33/135 - Bacteria or derivatives thereof, e.g. probiotics
• A61P 25/08 - AntiepilepticsAnticonvulsants

Abstract

The present invention addresses the problem of providing a method for obtaining a milk protein degradation product which has good emulsifiability despite a low-molecular-weight peptide. A method for producing a milk protein degradation product comprises a protein degradation step in which a proteolytic enzyme is made to act on the milk protein, wherein: the proteolytic enzyme comprises a trypsin-like endo-type protease derived from microorganisms, an endo-type protease derived from bacteria belonging to the genus Bacillus, and papain; and the number average molecular weight of the milk protein degradation product is 650 or less.

IPC Classes  ?

• A61K 38/01 - Hydrolysed proteinsDerivatives thereof
• A23J 3/08 - Dairy proteins
• A23J 3/34 - Working-up of proteins for foodstuffs by hydrolysis using chemical agents using enzymes

Abstract

The present invention addresses the problem of providing: a new food component that inhibits production of cortisol; and a composition containing the food component.　The present invention provides a composition that is for inhibiting production of cortisol, and that contains a milk-derived phospholipid.

IPC Classes  ?

• A23L 33/115 - Fatty acids or derivatives thereofFats or oils
• A23J 7/00 - Phosphatide compositions for foodstuffs, e.g. lecithin
• A61K 31/685 - Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
• A61K 35/20 - MilkWheyColostrum
• A61P 3/04 - AnorexiantsAntiobesity agents
• A61P 3/06 - Antihyperlipidemics
• A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
• A61P 5/38 - Drugs for disorders of the endocrine system of the suprarenal hormones
• A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• A61P 9/12 - Antihypertensives
• A61P 19/10 - Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
• A61P 21/00 - Drugs for disorders of the muscular or neuromuscular system
• A61P 25/20 - HypnoticsSedatives
• A61P 25/22 - Anxiolytics
• A61P 25/24 - Antidepressants
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• A61P 27/06 - Antiglaucoma agents or miotics
• A61P 37/02 - Immunomodulators
• A61P 43/00 - Drugs for specific purposes, not provided for in groups

Abstract

An aspect is to provide an active ingredient which can improve mitochondrial function. Another aspect is to provide a composition for suppressing muscle inflammation or muscular atrophy. One, two, or more kinds selected from a bacterium of the genus Akkermansia, a culture of the bacterium and a treated product of the bacterium are used as an active ingredient in a mitochondrial function-improving composition. The composition can be preferably applied for suppressing muscle inflammation or suppressing muscular atrophy.

IPC Classes  ?

• A61K 35/74 - Bacteria
• A23L 33/135 - Bacteria or derivatives thereof, e.g. probiotics
• A61P 21/00 - Drugs for disorders of the muscular or neuromuscular system

Abstract

A cognitive function-improving agent containing one or both of Bifidobacterium breve FERM BP-11175 and a culture of Bifidobacterium breve FERM BP-11175 as an active ingredient for administration to a subject who has not developed dementia is provided.

IPC Classes  ?

• A61K 35/745 - Bifidobacteria
• A23L 33/135 - Bacteria or derivatives thereof, e.g. probiotics
• C12N 1/20 - BacteriaCulture media therefor
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Abstract

A composition for promoting development of the intestinal tract, a composition for improving lung function or a composition for improving immune function containing a bacterium belonging to Bifidobacterium longum subsp. infantis is provided. The bacterium is preferably Bifidobacterium longum subsp. infantis M-63 (NITE BP-02623).

IPC Classes  ?

• A61K 35/745 - Bifidobacteria
• A61K 35/20 - MilkWheyColostrum
• A61K 31/702 - Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
• A61P 1/00 - Drugs for disorders of the alimentary tract or the digestive system
• A61P 37/04 - Immunostimulants

Abstract

An object of the present technology is to provide a nutritional composition having excellent emulsion stability. The present technology provides a nutritional composition containing a protein component, a lipid, and an organic acid ester of monoglyceride, wherein the organic acid ester of monoglyceride includes two or more kinds selected from acetic acid ester of monoglyceride, citric acid ester of monoglyceride, succinic acid ester of monoglyceride, diacetyl tartaric acid ester of monoglyceride, and lactic acid ester of monoglyceride. At least one kind among the organic acid esters of monoglyceride may be succinic acid ester of monoglyceride. Further, at least one kind among the organic acid ester of monoglyceride may be diacetyl tartaric acid ester of monoglyceride.

IPC Classes  ?

• A23L 33/12 - Fatty acids or derivatives thereof
• A23L 33/19 - Dairy proteins
• A61K 31/20 - Carboxylic acids, e.g. valproic acid having a carboxyl group bound to an acyclic chain of seven or more carbon atoms, e.g. stearic, palmitic or arachidic acid
• A61K 31/22 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
• A61K 35/20 - MilkWheyColostrum
• A61K 38/01 - Hydrolysed proteinsDerivatives thereof
• A61P 3/02 - Nutrients, e.g. vitamins, minerals

Abstract

A parent-and-child health study assistance system includes a data management section managing health study data used for a health study of at least one of a parent and a child in a family including a user as a family member, a level calculation section calculating a contribution level for the health study of the user based on input of the health study data, an incentive provision section providing the user with an incentive used as a profit corresponding to the contribution level, in conjunction with input of the health study data, an access control section managing an access authority to access the health study data, and an analysis result provision section providing an analysis result of analysis processing using the health study data.

IPC Classes  ?

• G16H 10/20 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for electronic clinical trials or questionnaires
• G06Q 30/0208 - Trade or exchange of goods or services in exchange for incentives or rewards
• G16H 20/60 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to nutrition control, e.g. diets
• G06F 21/62 - Protecting access to data via a platform, e.g. using keys or access control rules

Abstract

The purpose of the present technique is to provide a nutritional composition useful for preventing an immune dysfunction.　The present technique provides a nutritional composition containing a whey protein hydrolysate. The number-average molecular weight of the whey protein hydrolysate is 100-1,200, the whey protein hydrolysate includes a fraction having a molecular weight of 200-500, and the proportion of the area of the fraction having a molecular weight of 200-500 is 10-50% with respect to the total area in the molecular weight distribution curve of the whey protein hydrolysate. The nutritional composition may be used for supplementing the nutrition of persons who are infected. Moreover, the nutritional composition may be used for supplementing the nutrition of persons in an acute phase.

IPC Classes  ?

• A23L 33/18 - PeptidesProtein hydrolysates
• A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• A61P 3/02 - Nutrients, e.g. vitamins, minerals
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
• A61P 37/02 - Immunomodulators

Abstract

An analysis device in a parent-child health management system receives a sensor output from a sensor terminal and an answer to a questionnaire from a user terminal. At least one of parent's life information and child's life information is analyzed based on the answer to the questionnaire to generate a life information analysis result. A sensor output analysis unit generates, based on the sensor output, a sensing result including at least one of a parent-child relationship, a parent's health condition, and a child's health condition. A health estimation unit is configured to compare the life information analysis result and the sensing result with a predetermined criterion to estimate at least one of a parent-child state, a parent's state, and a child's state. An output unit is configured to select a questionnaire and advice corresponding to the estimated state and output the selected questionnaire and advice to the user terminal.

IPC Classes  ?

• G16H 10/20 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for electronic clinical trials or questionnaires

Abstract

longum, having utilization ability for 2′-fucosyllactose are also provided. More preferably, bacteria having utilization ability for carbohydrates arabinoxylan, arabinan, and pectic galactan; and a composition containing the bacteria are also provided. More preferably, a composition containing 2′-fucosyllactose are also provided. More preferably, a composition containing at least one carbohydrate selected from the group consisting of arabinoxylan, arabinan, pectic galactan, and oligosaccharides derived therefrom or containing at least a carbohydrate derived from a gramineous plant or a carbohydrate derived from a solanaceous plant are also provided.

IPC Classes  ?

• C12N 1/20 - BacteriaCulture media therefor
• A23L 2/52 - Adding ingredients
• A23L 33/00 - Modifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof
• A23L 33/125 - Modifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives containing carbohydrate syrupsModifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives containing sugarsModifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives containing sugar alcoholsModifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives containing starch hydrolysates
• A23L 33/135 - Bacteria or derivatives thereof, e.g. probiotics
• A61K 35/745 - Bifidobacteria
• A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
• A61K 47/36 - PolysaccharidesDerivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
• A61K 35/00 - Medicinal preparations containing materials or reaction products thereof with undetermined constitution

Abstract

A technique for promoting the assimilation of an oligosaccharide such as an HMO by an intestinal bacterium, especially a bifidobacterial strain, is provided. As a first aspect, a composition for promoting the assimilation of an oligosaccharide containing a tocopherol is provided. As a second aspect, a nutritional composition (excluding breast milk) containing an oligosaccharide and a tocopherol is provided. The tocopherol in the aspects contains one, two or more kinds selected from the group consisting of β-tocopherol, γ-tocopherol and δ-tocopherol. The oligosaccharide in the aspects is preferably a human milk oligosaccharides. The mass ratio of the δ-tocopherol content to the β-tocopherol content (δ/β) in the aspects is preferably 5 or more, and the mass ratio of the γ-tocopherol content to the δ-tocopherol content (γ/δ) is preferably 8.8 or less.

IPC Classes  ?

• A23L 33/15 - Vitamins
• A23L 33/00 - Modifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof
• A61K 31/355 - Tocopherols, e.g. vitamin E
• A61K 31/702 - Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages

Abstract

This prophylactic agent for brain atrophy is intended to be administered to any one subject selected from a normal person, a person who is diagnosed as having mild cognitive impairment, a person who is examined to be deteriorated in cognitive function, a subject who is at a risk of being affected by a neurodegenerative disease, and contains a culture containing Bifidobacterium breve MCC1274 (FERM BP-11175) as an active ingredient.

IPC Classes  ?

• A61K 35/745 - Bifidobacteria
• A23L 33/135 - Bacteria or derivatives thereof, e.g. probiotics
• A61P 25/00 - Drugs for disorders of the nervous system
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• C12N 1/20 - BacteriaCulture media therefor

Abstract

A mother and child health management system is connected to a plurality of terminals and includes: a reception unit configured to receive, as analysis information, information from each of the plurality of terminals and biological information from a medical care institution; a classification unit configured to identify, based on an analysis result of the analysis information, state values indicating a state of a mother, a state of a child, and a state between the mother and the child; an access authority management section configured to identify, based on each of the state values, a community to which a family including a user of the each of the plurality of terminals belongs, and configured to provide the terminal with an access authority to receive a display of a solution related to the community; and a display unit configured to display the solution related to the community on the terminal.

IPC Classes  ?

• G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indicesICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
• G16H 10/60 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records

Abstract

A problem addressed is to provide a useful means for increasing muscle mass. A composition containing threonic acid, one or more bacteria selected from Bifidobacterium spp., Lactobacillus spp., Lacticaseibacillus spp., Lactiplantibacillus spp., Limosilactobacillus spp., Levilactobacillus spp., Ligilactobacillus spp., and Latilactobacillus spp., and one or more selected from cultures of the aforementioned bacteria is used to increase muscle mass. Such a composition is produced through, e.g., a method that includes a step for culturing one or more bacteria selected from the aforementioned bacteria in ascorbic-acid-containing medium and a step for recovering a threonic-acid-containing fraction from the culture after culturing.

IPC Classes  ?

• C12P 7/40 - Preparation of oxygen-containing organic compounds containing a carboxyl group
• A23L 2/52 - Adding ingredients
• A23L 33/135 - Bacteria or derivatives thereof, e.g. probiotics
• A61K 31/191 - Acyclic acids having two or more hydroxy groups, e.g. gluconic acid
• A61K 35/744 - Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
• A61K 35/745 - Bifidobacteria
• A61K 35/747 - Lactobacilli, e.g. L. acidophilus or L. brevis
• A61P 21/06 - Anabolic agents

Abstract

The present invention addresses the problem of developing a more efficient method for producing aloe extract. The present invention provides a method for producing aloe extract, the method including the following steps: a step for obtaining an extract from dried aloe mesophyll through a supercritical fluid extraction method; and a step for carrying out oil-water separation on the extract obtained in the aforementioned step, and obtaining the resultant oil phase as an aloe extract.

IPC Classes  ?

• A23L 33/11 - Plant sterols or derivatives thereof, e.g. phytosterols
• A23L 2/52 - Adding ingredients
• A23L 33/105 - Plant extracts, their artificial duplicates or their derivatives
• A61K 8/9794 - Liliopsida [monocotyledons]
• A61K 36/886 - Aloeaceae (Aloe family), e.g. aloe vera
• A61Q 19/00 - Preparations for care of the skin
• C11B 1/10 - Production of fats or fatty oils from raw materials by extracting
• C11D 3/22 - Carbohydrates or derivatives thereof
• C11D 3/382 - Vegetable products, e.g. soya meal, wood flour, sawdust

Abstract

According to the invention, a novel Bifidobacterial strain having an ability of assimilating two or more kinds of HMO is provided. The strain is selected from the group consisting of Bifidobacterium longum subspecies infantis (NITE BP-03068), Bifidobacterium bifidum (NITE BP-03058) and Bifidobacterium bifidum (NITE BP-03067).

IPC Classes  ?

• C12N 1/20 - BacteriaCulture media therefor
• A23L 33/135 - Bacteria or derivatives thereof, e.g. probiotics

Abstract

Bifidobacterium bacteria as an active ingredient.

IPC Classes  ?

• A61K 35/745 - Bifidobacteria
• A23C 9/123 - Fermented milk preparationsTreatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceaeYoghurt
• A23L 33/00 - Modifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof
• A23L 33/135 - Bacteria or derivatives thereof, e.g. probiotics
• C12N 1/20 - BacteriaCulture media therefor

Abstract

According to the invention, a composition which can promote the growth of a Bifidobacterial strain which can be a good bacterium is provided. The composition contains a human milk oligosaccharide mixture containing lacto-N-neotetraose, lacto-N-tetraose, 2'-fucosyllactose, 3'-sialyllactose, 6'-sialyllactose and Bifidobacterium longum subspecies infantis.

IPC Classes  ?

• A23C 9/152 - Milk preparationsMilk powder or milk powder preparations containing additives
• A23L 33/125 - Modifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives containing carbohydrate syrupsModifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives containing sugarsModifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives containing sugar alcoholsModifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives containing starch hydrolysates
• A23L 33/135 - Bacteria or derivatives thereof, e.g. probiotics
• C12N 1/20 - BacteriaCulture media therefor

Abstract

The purpose of the present technique is to provide a nutritional composition for improving the intestinal environment.　The present technique provides a nutritional composition that contains indigestible dextrin and inulin, wherein the ratio by mass of the indigestible dextrin in prebiotic component is 100 times or less than the ratio by mass of inulin in the prebiotic component. Preferably, the ratio by mass of the indigestible dextrin in the prebiotic component is 0.2-100 times inclusive than the ratio by mass of inulin in the prebiotic component.

IPC Classes  ?

• A23L 29/244 - Foods or foodstuffs containing additivesPreparation or treatment thereof containing gelling or thickening agents of vegetable origin from corms, tubers or roots, e.g. glucomannan
• A23L 29/30 - Foods or foodstuffs containing additivesPreparation or treatment thereof containing carbohydrate syrupsFoods or foodstuffs containing additivesPreparation or treatment thereof containing sugarsFoods or foodstuffs containing additivesPreparation or treatment thereof containing sugar alcohols, e.g. xylitolFoods or foodstuffs containing additivesPreparation or treatment thereof containing starch hydrolysates, e.g. dextrin
• A23L 33/125 - Modifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives containing carbohydrate syrupsModifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives containing sugarsModifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives containing sugar alcoholsModifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives containing starch hydrolysates
• A23L 33/135 - Bacteria or derivatives thereof, e.g. probiotics
• A23L 33/21 - Addition of substantially indigestible substances, e.g. dietary fibres
• A23L 33/22 - Comminuted fibrous parts of plants, e.g. bagasse or pulp
• A23L 33/26 - Polyol polyesters, e.g. sucrose polyestersSynthetic sugar polymers, e.g. polydextrose

Abstract

The present invention addresses the problem of providing a nutritional composition that has high calories and that has excellent emulsification stability even when the contained amount of an emulsifier is less.　This nutritional composition contains lipids, carbohydrates, and an emulsifier. The contained amount of the lipids in the nutritional composition is 3.5 g/100kcal or more. The contained amount of the emulsifier in the nutritional composition is 0.60 g/100kcal or less. In the lipids, the proportion of medium chain fatty acids in the total constitutional fatty acids is 20 mass% or more.

IPC Classes  ?

• A23L 33/12 - Fatty acids or derivatives thereof
• A23D 7/00 - Edible oil or fat compositions containing an aqueous phase, e.g. margarines
• A23D 7/005 - Edible oil or fat compositions containing an aqueous phase, e.g. margarines characterised by ingredients other than fatty acid triglycerides
• A23L 33/125 - Modifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives containing carbohydrate syrupsModifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives containing sugarsModifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives containing sugar alcoholsModifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives containing starch hydrolysates

Abstract

The present invention provides a protein-containing composition that can be ingested without reducing the intake, and without placing a burden on the kidney and the liver. Provided is a protein-containing composition for enteral intake, the composition including at least 81% by mass micellar casein with respect to the total protein, which composition is for ingestion by a subject requiring suppression or prevention of a decline(s) in renal function and/or liver function.

IPC Classes  ?

• A23K 20/147 - Polymeric derivatives, e.g. peptides or proteins
• A23K 10/20 - Animal feeding-stuffs from material of animal origin

Abstract

An aspect is to provide a prebiotic for growing a butyrate-producing bacterium. A prebiotic composition for a butyrate-producing bacterium includes alginic acid and/or a salt thereof having an average molecular weight of 10000 or less.

IPC Classes  ?

• A23L 33/10 - Modifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives
• A23L 33/135 - Bacteria or derivatives thereof, e.g. probiotics
• A61K 31/734 - Alginic acid

Abstract

The present invention addresses the problem of providing a technique for promoting various bacteria of the genus Bifidobacterium in intestinal flora. A prebiotic composition for bacteria of the genus Bifidobacterium is obtained by combining 1-kestose and galactooligosaccharide. The composition can proliferate one or two or more kinds of bacteria of the genus Bifidobacterium selected from the group consisting of Bifidobacterium longum, Bifidobacterium breve, Bifidobacterium infantis, and Bifidobacterium bifidum.

IPC Classes  ?

• A23L 33/125 - Modifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives containing carbohydrate syrupsModifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives containing sugarsModifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives containing sugar alcoholsModifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives containing starch hydrolysates
• A23C 9/152 - Milk preparationsMilk powder or milk powder preparations containing additives
• A23L 33/135 - Bacteria or derivatives thereof, e.g. probiotics
• A61K 31/702 - Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
• A61K 31/715 - Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkagesDerivatives thereof, e.g. ethers, esters
• A61K 35/745 - Bifidobacteria
• A61P 1/00 - Drugs for disorders of the alimentary tract or the digestive system
• C12N 1/20 - BacteriaCulture media therefor

Abstract

An electrolyzed water generator according to one embodiment is provided with: a first electrolysis cell which is provided with an electrolyte solution chamber, a positive electrode chamber that is divided from the electrolyte solution chamber by means of a first diaphragm, a negative electrode chamber that is divided from the electrolyte solution chamber by means of a second diaphragm, a positive electrode that is arranged in the positive electrode chamber so as to face the first diaphragm, a first negative electrode that is arranged in the negative electrode chamber so as to face the second diaphragm, a second negative electrode that is arranged in the electrolyte solution chamber so as to face the positive electrode with the first diaphragm being interposed therebetween, and a third diaphragm that is arranged between the second negative electrode and the first diaphragm so as to divide the inside of the electrolyte solution chamber into a first electrolyte solution chamber which is on the positive electrode chamber side and a second electrolyte solution chamber which is on the negative electrode chamber side; a first feeding unit which feeds power to the positive electrode, the first negative electrode and the second negative electrode; a switch which applies a current from the feeding unit to the first negative electrode and/or the second negative electrode; and a first product water mixing unit which forms a first mixed product water by mixing product water at the positive electrode and product water at the negative electrode with each other, said product waters being obtained by electrolyzing an electrolyte solution in the first electrolysis cell.

IPC Classes  ?

• C02F 1/461 - Treatment of water, waste water, or sewage by electrochemical methods by electrolysis

Abstract

A method for producing a meat-like food product comprises the steps of: mixing ingredients comprising tofu, water-soluble dietary fibers derived from grain, and gluten to prepare a dough; shaping the dough into a shaped product; and heating the shaped product.

IPC Classes  ?

• A23J 3/16 - Vegetable proteins from soybean
• A21D 6/00 - Other treatment of flour or dough before baking, e.g. cooling, irradiating or heating
• A21D 2/26 - Proteins
• A23J 3/22 - Working-up of proteins for foodstuffs by texturising
• A21D 2/16 - Fatty acid esters

Abstract

The present invention provides: a peptide that can be readily consumed on a daily basis and has various effects but few side effects; and a composition that contains the peptide as an active ingredient.　Provided is a peptide that comprises the amino acid sequence of (a) or (b). (a) The amino acid sequence of SEQ ID NO:1 (Asn-Leu-Pro-Pro-Leu-Thr). (b) An amino acid sequence produced from the amino acid sequence of SEQ ID NO:1 by adding, deleting, or replacing one or more amino acids. Also provided is a composition that contains the peptide as an active ingredient.

IPC Classes  ?

• C07K 7/06 - Linear peptides containing only normal peptide links having 5 to 11 amino acids
• A23L 33/18 - PeptidesProtein hydrolysates
• A61K 38/08 - Peptides having 5 to 11 amino acids
• A61P 25/20 - HypnoticsSedatives
• A61P 25/22 - Anxiolytics
• A61P 25/24 - Antidepressants
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• C07K 1/12 - General processes for the preparation of peptides by hydrolysis
• C12P 21/06 - Preparation of peptides or proteins produced by the hydrolysis of a peptide bond, e.g. hydrolysate products

Abstract

The present invention addresses the problem of providing a technology for improving quality of life (QOL), preferably, to provide a technology for ameliorating insomnia, for ameliorating fatigue, or for improving gastrointestinal regulation. This problem is solved by a composition for improving QOL, which contains Lactobacillus helveticus.

IPC Classes  ?

• A61P 1/14 - Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
• A61P 3/00 - Drugs for disorders of the metabolism
• A61P 25/20 - HypnoticsSedatives
• A61K 35/747 - Lactobacilli, e.g. L. acidophilus or L. brevis
• A23L 33/135 - Bacteria or derivatives thereof, e.g. probiotics

Abstract

The present invention addresses the problem of providing a technique for further promoting the proliferation of a plurality of major species of bacteria belonging to the genus Bifidobacterium in the intestinal flora. Oligosaccharides including galactooligosaccharide, lactulose, and raffinose are used as prebiotics for bacteria belonging to the genus Bifidobacterium including Bifidobacterium longum, Bifidobacterium breve, Bifidobacterium infantis, and Bifidobacterium bifidum. Provided is a composition containing the oligosaccharides and the bacteria belonging to the genus Bifidobacterium. Moreover, provided is a composition for promoting the proliferation of bacteria belonging to the genus Bifidobacterium, the composition containing the oligosaccharides.

IPC Classes  ?

• A61P 3/02 - Nutrients, e.g. vitamins, minerals
• A61P 43/00 - Drugs for specific purposes, not provided for in groups
• A61K 35/745 - Bifidobacteria
• A61K 31/702 - Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
• A23C 9/152 - Milk preparationsMilk powder or milk powder preparations containing additives
• A23L 29/30 - Foods or foodstuffs containing additivesPreparation or treatment thereof containing carbohydrate syrupsFoods or foodstuffs containing additivesPreparation or treatment thereof containing sugarsFoods or foodstuffs containing additivesPreparation or treatment thereof containing sugar alcohols, e.g. xylitolFoods or foodstuffs containing additivesPreparation or treatment thereof containing starch hydrolysates, e.g. dextrin
• A23L 33/125 - Modifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives containing carbohydrate syrupsModifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives containing sugarsModifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives containing sugar alcoholsModifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives containing starch hydrolysates
• A23L 33/135 - Bacteria or derivatives thereof, e.g. probiotics
• A23L 33/21 - Addition of substantially indigestible substances, e.g. dietary fibres

Abstract

A problem of the invention is to provide a technique for improving memory ability in later childhood, and the problem is solved by a composition for an infant and/or child for improving memory ability in later childhood, wherein the composition contains Bifidobacterium longum subsp. infantis as an active ingredient.

IPC Classes  ?

• A61K 35/745 - Bifidobacteria
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Abstract

The present invention addresses the problem of providing a peptide having excellent dipeptidyl peptidase-IV (DPP-IV) inhibitory activity. An oligopeptide including any of the sequences described in (a) to (h) below. These oligopeptides may be an effective ingredient of the DPP-IV inhibitor. (a) Leu-Pro-Val, (b) Ile-Pro-Thr, (c) Pro-Pro-Gln, (d) Ala-Pro-Phe, (e) Pro-Pro-Leu, (f) Pro-Pro-Phe, (g) Ala-Pro-Ser, (h) Leu-Pro-Val-Pro

IPC Classes  ?

• C07K 5/08 - Tripeptides
• A23J 3/08 - Dairy proteins
• A23J 3/30 - Working-up of proteins for foodstuffs by hydrolysis
• A23L 33/18 - PeptidesProtein hydrolysates
• A61K 35/20 - MilkWheyColostrum
• A61K 38/06 - Tripeptides
• A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
• A61P 43/00 - Drugs for specific purposes, not provided for in groups

Abstract

Provided is a frozen dessert in which the formation of ice on the surface thereof is suppressed during storage in a frozen state.　This frozen dessert is formed of a composition that contains at least one specific component selected from the group consisting of pullulan, tremel gum, starch, trehalose, powdered candy and gelatin, and water.

IPC Classes  ?

• A23G 9/24 - Details, component parts or accessories of apparatus insofar as not peculiar to a single one of the preceding groups for coating or filling the products

Abstract

A method for producing a frozen dessert according to the present invention comprises a step in which a first frozen dessert material (11) is inserted into a mold (2), a portion thereof contacting the inner surface of the mold (2) is hardened to form a shell layer (11b), a second frozen dessert material (12) is then inserted into the mold (2), a remaining portion (11c) of the first frozen dessert material is hardened, and a frozen dessert molded using a mold is obtained. The viscosity of the first frozen dessert material at the insertion temperature is 4000 mPa·s or less, and the viscosity of the second frozen dessert material at the insertion temperature is 3000 mPa·s or less. The specific gravity of the second frozen dessert material at the insertion temperature is greater than the specific gravity of the first frozen dessert material at the insertion temperature, and the difference thereof is 0.06 or greater.

IPC Classes  ?

• A23G 9/24 - Details, component parts or accessories of apparatus insofar as not peculiar to a single one of the preceding groups for coating or filling the products
• A23G 9/48 - Composite products, e.g. layered, coated, filled

Abstract

The present invention addresses the problem of providing a composition capable of maintaining, improving, or enhancing immune function by activating plasmacytoid dendritic cells (pDCs). Lactoferrin and/or a lactoferrin hydrolysate is incorporated as an active ingredient into this composition for pDC activation. The pDC activation can include an increase in one or more selected from the group consisting of the proportion of pDCs among mononuclear cells, the proportion of CD86+ cells among pDCs, the CD86 expression level in pDCs, and the HLA-DR expression level in pDCs. The composition can be ingested in the form of a food/beverage or a pharmaceutical.

IPC Classes  ?

• A61P 37/04 - Immunostimulants
• A61P 43/00 - Drugs for specific purposes, not provided for in groups
• A61K 38/40 - Transferrins, e.g. lactoferrins, ovotransferrins
• A23L 33/19 - Dairy proteins

Abstract

An object of the present invention is to provide a technique for further promoting growth of bacteria belonging to the genus Bifidobacterium. By combining lactoferrin and/or lactoferrin hydrolyzate, and human milk oligosaccharides, a synergistic growth promoting effect of the bacteria belonging to the genus Bifidobacterium is achieved. Preferably, the human milk oligosaccharides include one or more selected from the group consisting of 2′-fucosyllactose, 3-fucosyllactose, and lactodifucotetraose. In addition, preferably, the bacteria belonging to the genus Bifidobacterium include one or more selected from the group consisting of Bifidobacterium breve, Bifidobacterium infantis, and Bifidobacterium longum.

IPC Classes  ?

• A61K 35/745 - Bifidobacteria
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 38/40 - Transferrins, e.g. lactoferrins, ovotransferrins
• A61K 35/20 - MilkWheyColostrum
• A61K 31/702 - Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
• A23L 33/00 - Modifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof
• A23L 33/19 - Dairy proteins

Abstract

An object of the present invention is to provide a technique for preventing infection of pathogenic viruses, which cause infectious diseases in animals or humans. A nutritional composition containing lactoferrin and/or lactoferrin hydrolysate, and human milk oligosaccharide is provided. One or more human milk oligosaccharides are preferably 2′-fucosyllactose, 3-fucosyllactose, 3′-sialyllactose, and 6′-sialyllactose. The nutritional compositions of the present invention can be used for preventing infection, especially for preventing viral infection.

IPC Classes  ?

• A61K 35/20 - MilkWheyColostrum
• A61K 38/40 - Transferrins, e.g. lactoferrins, ovotransferrins
• A61K 31/702 - Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A23L 33/125 - Modifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives containing carbohydrate syrupsModifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives containing sugarsModifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives containing sugar alcoholsModifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives containing starch hydrolysates
• A23L 33/19 - Dairy proteins
• A23L 33/00 - Modifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof

Abstract

The invention provides a composition which contains a bacterial powder and a fatty oil and in which caking of the bacterial powder is suppressed, a method for producing the same, and a method of preventing caking. Provided are a composition including a bacterial powder, a fatty oil, and at least one selected from the group consisting of a microscopic powder and a surfactant, wherein the bacterial powder comprises at least one selected from the group consisting of live cells of lactic acid bacteria, killed cells of lactic acid bacteria, live cells of bifidobacteria, and killed cells of bifidobacteria, a method for producing the same, and a method of preventing caking in a composition containing a fatty oil.

IPC Classes  ?

• A61K 35/747 - Lactobacilli, e.g. L. acidophilus or L. brevis
• A61K 35/745 - Bifidobacteria
• A61K 47/12 - Carboxylic acidsSalts or anhydrides thereof
• A61K 47/38 - CelluloseDerivatives thereof
• A61K 47/02 - Inorganic compounds
• A61K 47/44 - Oils, fats or waxes according to two or more groups of Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin

Abstract

The present invention addresses the problem of providing prebiotics that efficiently proliferate butyric acid bacteria. The prebiotic composition for butyric acid bacteria has, as an active ingredient thereof, an oligosaccharide, or a salt thereof, that comprises a β–D–mannuronic acid and/or an α–L–gluuronic acid and has an unsaturated β–D–mannuronic acid residue or an α–L–gluuronic acid residue on a non-reducing terminal thereof. This oligosaccharide can be produced by causing alginate lyase to act on alginate and/or a salt thereof or a hydrolysate thereof and obtaining an alginate decomposition product.

IPC Classes  ?

• A61P 1/00 - Drugs for disorders of the alimentary tract or the digestive system
• A61P 1/12 - Antidiarrhoeals
• A61P 1/14 - Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
• C12N 1/20 - BacteriaCulture media therefor
• C12N 9/88 - Lyases (4.)
• A61K 35/741 - Probiotics
• A61K 31/715 - Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkagesDerivatives thereof, e.g. ethers, esters
• A61K 31/734 - Alginic acid
• C12P 7/40 - Preparation of oxygen-containing organic compounds containing a carboxyl group
• A23L 33/125 - Modifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives containing carbohydrate syrupsModifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives containing sugarsModifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives containing sugar alcoholsModifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives containing starch hydrolysates

Abstract

Bifidobacterium and a composition for promoting the intestinal colonization of the bacterium.

IPC Classes  ?

• A61K 31/192 - Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
• A23K 10/18 - Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions of live microorganisms
• A23K 20/111 - Aromatic compounds
• A23L 2/52 - Adding ingredients
• A23L 33/135 - Bacteria or derivatives thereof, e.g. probiotics
• A61K 35/00 - Medicinal preparations containing materials or reaction products thereof with undetermined constitution
• A61K 35/742 - Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
• A61K 35/745 - Bifidobacteria
• A61P 1/00 - Drugs for disorders of the alimentary tract or the digestive system

Abstract

Provided is a novel food and drink which can continuously increase the lactic acid concentration in the blood.　This food and drink contains a lactic acid compound and fructose, wherein the content of the lactic acid compound is 3-75 g in terms of lactic acid, and the content of the fructose is 7-150 g.

IPC Classes  ?

• A61P 3/02 - Nutrients, e.g. vitamins, minerals
• A61P 43/00 - Drugs for specific purposes, not provided for in groups
• A23L 33/12 - Fatty acids or derivatives thereof
• A23L 33/125 - Modifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives containing carbohydrate syrupsModifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives containing sugarsModifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives containing sugar alcoholsModifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives containing starch hydrolysates
• A23L 2/52 - Adding ingredients
• A23L 2/60 - Sweeteners
• A23L 2/68 - Acidifying substances
• A61K 31/19 - Carboxylic acids, e.g. valproic acid
• A61K 31/7004 - Monosaccharides having only carbon, hydrogen and oxygen atoms

Abstract

∞0∞∞ is acquired by fitting the stress S measured in the stress relaxation test into a predetermined equation (1).

IPC Classes  ?

• A23L 29/269 - Foods or foodstuffs containing additivesPreparation or treatment thereof containing gelling or thickening agents of microbial origin, e.g. xanthan or dextran

Abstract

The present invention addresses the problem of providing a technique for regulating expression of a gene involved in the production or degradation of collagen, elastin, or hyaluronic acid. This problem is solved by using a composition, for regulating the expression of a gene involved in the production or degradation of collagen, elastin or hyaluronic acid, which includes Bifidobacterium Breve M-16V (NITE BP-02622) or a culture supernatant thereof as an active ingredient, wherein the gene is selected from the collagen-degrading enzyme 1 gene (MMP1), the type I collagen gene (COL1A1), the elastin gene (ELN), the hyaluronic acid synthase 1 gene (HAS1), and the hyaluronic acid synthase 2 gene (HAS2).

IPC Classes  ?

• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• A61P 9/14 - VasoprotectivesAntihaemorrhoidalsDrugs for varicose therapyCapillary stabilisers
• A61P 19/00 - Drugs for skeletal disorders
• A61P 19/02 - Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
• A61P 43/00 - Drugs for specific purposes, not provided for in groups
• A61P 17/00 - Drugs for dermatological disorders
• A23L 33/135 - Bacteria or derivatives thereof, e.g. probiotics
• C12N 1/20 - BacteriaCulture media therefor
• C12N 15/12 - Genes encoding animal proteins
• C12N 15/57 - Hydrolases (3) acting on peptide bonds (3.4)
• C12N 15/60 - Lyases (4)
• A61K 35/745 - Bifidobacteria

Abstract

The present invention addresses the problem of providing the development of a simpler, more efficient method for producing a phytosterol starting material. The present invention is a method for producing a phytosterol starting material, the method comprising a step (1) and a step (2), where step (1) is a step for obtaining a pressing residue by pressing aloe mesophyll, and step (2) is a step for obtaining a dried pressing residue by drying the pressing residue obtained in step (1).

IPC Classes  ?

• C07J 9/00 - Normal steroids containing carbon, hydrogen, halogen, or oxygen, substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
• C07J 53/00 - Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by condensation with carbocyclic rings or by formation of an additional ring by means of a direct link between two ring carbon atoms
• A23L 33/11 - Plant sterols or derivatives thereof, e.g. phytosterols

Abstract

A problem is to provide a prebiotic which promotes the growth of a butyrate-producing bacterium. A prebiotic composition is described that promotes the growth of a butyrate-producing bacterium which contains alginic acid and/or a salt thereof.

IPC Classes  ?

• A61K 31/734 - Alginic acid
• C12N 1/20 - BacteriaCulture media therefor
• A23L 33/21 - Addition of substantially indigestible substances, e.g. dietary fibres

Abstract

An object of this present invention is to provide a composition for inhibiting norovirus infection which can inhibit norovirus from infecting a human, and the object is achieved by a composition for inhibiting norovirus infection containing one or more kinds of bacteria selected from the group consisting of Bifidobacterium breve, Bifidobacterium longum subsp. infantis, Bifidobacterium animalis, Bifidobacterium bifidum, Bifidobacterium catenulatum, Lactobacillus gasseri, Lactobacillus helveticus, Lactobacillus delbrueckii subsp. Bulgaricus and Lactobacillus paracasei as an active ingredient.

IPC Classes  ?

• A23L 33/135 - Bacteria or derivatives thereof, e.g. probiotics
• A23L 33/19 - Dairy proteins
• A61K 35/745 - Bifidobacteria
• A61K 35/747 - Lactobacilli, e.g. L. acidophilus or L. brevis

Abstract

This maternal and child health management system comprises: a reception unit which connects to a plurality of terminals and receives, as analysis information, information from a terminal and biometric information from medical institutions; a classification unit which specifies, on the basis of the analysis result of the analysis information, each state value of the state of the mother, the state of the child, and the state between the mother and the child; an authority management unit which specifies, on the basis of each state value, a belonging community of the family of a user who uses a terminal, and grants access authority to receive presented solutions related to the belonging community; and a presentation unit which presents solutions related to the belonging community to the terminal.

IPC Classes  ?

• G16H 80/00 - ICT specially adapted for facilitating communication between medical practitioners or patients, e.g. for collaborative diagnosis, therapy or health monitoring

Abstract

In this parent-child health management system, an analysis device comprises: a reception unit for receiving sensor output of a sensor terminal and response of questionnaire input to a user terminal; a questionnaire analysis unit for analyzing at least one of living information of a parent and living information of a child from the response of the questionnaire to generate a living information analysis result; a sensor output analysis unit for generating, on the basis of the sensor output, a sensing result including at least one of a relationship between the parent and the child, a health condition of the parent, and a health condition of the child; a health estimation unit for comparing the living information analysis result and the sensing result with a predetermined criteria defined in advance to estimate at least one of a condition of the parent and the child, a condition of the parent, and a condition of the child; and an output unit for selecting a questionnaire and advice corresponding to the estimated state and outputting the selected questionnaire and advice to the user terminal.

IPC Classes  ?

• G06Q 50/10 - Services
• G16H 10/20 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for electronic clinical trials or questionnaires
• G16H 20/00 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
• G16H 80/00 - ICT specially adapted for facilitating communication between medical practitioners or patients, e.g. for collaborative diagnosis, therapy or health monitoring

Abstract

Provided is a cognitive function improving agent which is administered to a subject who has not developed dementia, and which contains, as an active ingredient, one or both of Bifidobacterium breve FERM BP-11175 and a culture of Bifidobacterium breve FERM BP-11175.

IPC Classes  ?

• A61K 35/745 - Bifidobacteria
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Abstract

This parent-child health survey assistance system comprises: a data management unit that manages health survey data to be used in a health survey of at least either one of a parent and a child in a family having users as constituent members; a level calculation unit that calculates a level representing the extent of a user's health survey contribution made via the inputting of health survey data; an incentive provision unit that, in conjunction with the inputting of the health survey data, provides the user with an incentive, which is a benefit corresponding to the level; an access control unit that manages access authority for the health survey data; and an analysis result provision unit that provides analysis results from analysis which used the health survey data.

IPC Classes  ?

• G16H 20/00 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance

Abstract

The present invention addresses the problem of providing an active ingredient capable of improving mitochondrial function. The present invention also addresses the problem of providing a composition for suppressing muscular inflammation or muscular atrophy. This mitochondrial function-improving composition contains, as an active ingredient, one or more selected from bacteria belonging to the genus Akkermansia, cultures of the bacteria, and processed products of the bacteria. The composition can be suitably applied to usage in muscular inflammation suppression and muscular atrophy suppression.

IPC Classes  ?

• A61K 35/74 - Bacteria
• A23L 33/135 - Bacteria or derivatives thereof, e.g. probiotics
• A61K 9/08 - Solutions
• A61K 9/10 - DispersionsEmulsions
• A61K 9/14 - Particulate form, e.g. powders
• A61K 9/16 - AgglomeratesGranulatesMicrobeadlets
• A61K 9/20 - Pills, lozenges or tablets
• A61K 9/48 - Preparations in capsules, e.g. of gelatin, of chocolate
• A61P 21/00 - Drugs for disorders of the muscular or neuromuscular system
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
• A61P 43/00 - Drugs for specific purposes, not provided for in groups
• C12N 1/20 - BacteriaCulture media therefor

Abstract

Provided is a composition for promoting intestinal tract development, a composition for improving pulmonary function or a composition for enhancing immune function, said composition containing a bacterium belonging to Bifidobacterium longum subspecies infantis. Preferably, the bacterium is Bifidobacterium longum subspecies infantis M-63 (NITE BP-02623).

IPC Classes  ?

• A61K 35/745 - Bifidobacteria
• A23L 33/135 - Bacteria or derivatives thereof, e.g. probiotics
• A61K 31/702 - Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
• A61P 1/00 - Drugs for disorders of the alimentary tract or the digestive system
• A61P 11/00 - Drugs for disorders of the respiratory system
• A61P 37/00 - Drugs for immunological or allergic disorders
• A23C 9/152 - Milk preparationsMilk powder or milk powder preparations containing additives
• A23C 9/18 - Milk in dried and compressed or semi-solid form

Abstract

Provided is a fermentation composition which includes (A) whey protein, (B) bifidobacterium bacteria, and (C) at least 0.05 mass% of ash content, and can suppress a decrease in the viable count of the bifidobacterium bacteria.

IPC Classes  ?

• A23C 21/02 - WheyWhey preparations containing, or treated with, microorganisms or enzymes
• A23C 21/10 - WheyWhey preparations containing inorganic additives
• A23L 2/52 - Adding ingredients
• A23L 2/38 - Other non-alcoholic beverages

Abstract

The present invention addresses the problem of providing a supercritical fluid extraction device capable of achieving high collection efficiency whether a target product is solid or semi-solid, and a method for manufacturing a target product using the same. A supercritical fluid extraction device (1) uses a supercritical fluid F to produce a target product p, the supercritical fluid extraction device (1) comprising: an extraction tank A which houses a raw material P of the target product p and to which the supercritical fluid F is supplied; a separation tank B that separates the target product p from the supercritical fluid F; and a collection container that houses the target product p, where the collection container C is detachably disposed inside the separation tank B.

IPC Classes  ?

• B01D 11/00 - Solvent extraction
• A61K 36/886 - Aloeaceae (Aloe family), e.g. aloe vera
• A23L 19/00 - Products from fruits or vegetablesPreparation or treatment thereof

Abstract

The present invention provides a composition capable of promoting the growth of a bacterium of the genus Bifidobacterium that can act as a beneficial bacterium. This composition comprises a mixture of human milk oligosaccharides, said mixture consisting of lacto-N-neotetraose, lacto-N-tetraose, 2'-fucosyllactose, 3'-sialyllactose and 6'-sialyllactose, together with Bifidobacterium longum subspecies infantis.

IPC Classes  ?

• A23C 9/152 - Milk preparationsMilk powder or milk powder preparations containing additives
• A23L 33/125 - Modifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives containing carbohydrate syrupsModifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives containing sugarsModifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives containing sugar alcoholsModifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives containing starch hydrolysates
• A23L 33/135 - Bacteria or derivatives thereof, e.g. probiotics
• C12N 1/20 - BacteriaCulture media therefor

Abstract

The present invention provides a novel Bifidobacterium bacterium that is capable of producing at least two types of human milk oligosaccharides (HMOs). This bacterium is selected from the group consisting of bifidobacterium longum subspecies infantis (NITE BP-03068), bifidobacterium bifidum (NITE BP-03058), and bifidobacterium bifidum (NITE BP-03067).

IPC Classes  ?

• C12N 1/20 - BacteriaCulture media therefor
• A23L 33/135 - Bacteria or derivatives thereof, e.g. probiotics

Abstract

A composition usable for a specific use, such as a composition for improving neurite outgrowth is provided. Such a composition is provided by using indole-3-lactic acid (ILA) or an indole-3-lactic acid-producing bacterium is used as an active ingredient.

IPC Classes  ?

• A23L 33/10 - Modifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives
• A23L 33/135 - Bacteria or derivatives thereof, e.g. probiotics
• A61K 31/404 - Indoles, e.g. pindolol
• A61K 35/745 - Bifidobacteria
• A61P 25/00 - Drugs for disorders of the nervous system
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Abstract

The present invention addresses the problem of providing a composition against aging. One or more substances selected from among Bifidobacterium longum NITE BP-02621, cultures thereof, and treated products thereof are included in an anti-aging composition. The composition of the present invention preferably makes it possible to obtain an anti-aging effect by cell senescence inhibitory activity and/or mitochondrial function improvement activity. Furthermore, the composition of the present invention can be suitably used for the purpose of extending life and/or suppressing hypokinesia.

IPC Classes  ?

• A61P 43/00 - Drugs for specific purposes, not provided for in groups
• C12P 1/04 - Preparation of compounds or compositions, not provided for in groups , by using microorganisms or enzymesGeneral processes for the preparation of compounds or compositions by using microorganisms or enzymes by using bacteria
• A23L 33/10 - Modifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives
• A23L 33/135 - Bacteria or derivatives thereof, e.g. probiotics
• C12N 1/20 - BacteriaCulture media therefor
• A61K 35/745 - Bifidobacteria
• A23L 2/52 - Adding ingredients
• A23L 2/38 - Other non-alcoholic beverages

Abstract

A novel agent useful for improving brain function is provided. The active ingredient in this agent is a Bifidobacterium breve and/or a Bifidobacterium breve-containing cultured material is provided.

IPC Classes  ?

• A61K 35/745 - Bifidobacteria
• A23L 33/135 - Bacteria or derivatives thereof, e.g. probiotics
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• A61P 25/18 - Antipsychotics, i.e. neurolepticsDrugs for mania or schizophrenia
• C12N 1/20 - BacteriaCulture media therefor
• A61P 25/24 - Antidepressants

Abstract

Bifidobacterium and/or lactobacilli as an active ingredient, and is used for a pre-obesity group or an obesity disease including intestinal flora in which the ratio of the phylum Firmicutes to the phylum Bacteroidetes has a high value.

IPC Classes  ?

• A61K 35/745 - Bifidobacteria
• A61K 35/00 - Medicinal preparations containing materials or reaction products thereof with undetermined constitution
• A61K 35/747 - Lactobacilli, e.g. L. acidophilus or L. brevis

Abstract

The present invention addresses the problem of providing a protein-containing composition that can be consumed without reducing the intake and without placing stress on the kidney and liver. Provided is a protein-containing composition for enteral intake, the composition containing micellar casein in an amount of at least 81% by mass of the total protein and being designed to be taken by a subject in need of suppression or prevention of reduced renal function and/or hepatic function.

IPC Classes  ?

• A61P 3/02 - Nutrients, e.g. vitamins, minerals
• A23K 10/20 - Animal feeding-stuffs from material of animal origin
• A23K 20/147 - Polymeric derivatives, e.g. peptides or proteins
• A23L 33/17 - Amino acids, peptides or proteins
• A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans

Abstract

longum, having utilization ability for 2′-fucosyllactose are also provided. More preferably, bacteria having utilization ability for carbohydrates arabinoxylan, arabinan, and pectic galactan; and a composition containing the bacteria are also provided. More preferably, a composition containing 2′-fucosyllactose are also provided. More preferably, a composition containing at least one carbohydrate selected from the group consisting of arabinoxylan, arabinan, pectic galactan, and oligosaccharides derived therefrom or containing at least a carbohydrate derived from a gramineous plant or a carbohydrate derived from a solanaceous plant are also provided.

IPC Classes  ?

• A61K 35/745 - Bifidobacteria
• C12N 1/20 - BacteriaCulture media therefor
• A23L 33/125 - Modifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives containing carbohydrate syrupsModifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives containing sugarsModifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives containing sugar alcoholsModifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives containing starch hydrolysates
• A23L 33/135 - Bacteria or derivatives thereof, e.g. probiotics
• A23L 33/00 - Modifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof
• A23L 2/52 - Adding ingredients
• A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
• A61K 47/36 - PolysaccharidesDerivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
• A61K 35/00 - Medicinal preparations containing materials or reaction products thereof with undetermined constitution

Abstract

There is provided a means for sterilizing lactoferrin at a high temperature in a short time while maintaining the activity of the lactoferrin. The present technology provides a method for producing a lactoferrin-containing aqueous solution, including a sterilization step of heat-sterilizing a lactoferrin-containing aqueous solution, in which the total mass content of proteins other than lactoferrin is 1/12 or less of the mass content of lactoferrin, at a temperature of 100° C. or more. The present technology also provides a lactoferrin-containing aqueous solution in which the total mass content of proteins other than lactoferrin is 1/12 or less of the mass content of lactoferrin, and which does not contain living bacteria.

IPC Classes  ?

• A23J 3/08 - Dairy proteins
• A23J 1/20 - Obtaining protein compositions for foodstuffsBulk opening of eggs and separation of yolks from whites from milk, e.g. caseinObtaining protein compositions for foodstuffsBulk opening of eggs and separation of yolks from whites from whey

Abstract

Provided are: a composition that includes bacterium powder and fatty oil and has suppressed caking of the bacterium powder; a production method; and a usage.　A composition including bacterium powder, fatty oil, and at least one type selected from the group consisting of a micro-powder and a surfactant; a production method therefor; and a usage as an anti-caking agent for bacterium powder, in at least one type of composition that includes fatty oil and is selected from the group consisting of a micro-powder and a surfactant.

IPC Classes  ?

• A23L 33/135 - Bacteria or derivatives thereof, e.g. probiotics
• A61K 35/741 - Probiotics

Abstract

Bifidobacterium as an active ingredient is described.

IPC Classes  ?

• A61K 35/745 - Bifidobacteria
• A23C 9/152 - Milk preparationsMilk powder or milk powder preparations containing additives
• A23L 33/135 - Bacteria or derivatives thereof, e.g. probiotics
• A61K 38/21 - Interferons

Abstract

Bifidobacterium bacteria as an active ingredient.

IPC Classes  ?

• A61K 35/745 - Bifidobacteria
• A23L 33/135 - Bacteria or derivatives thereof, e.g. probiotics
• A23L 33/00 - Modifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof
• A23C 9/123 - Fermented milk preparationsTreatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceaeYoghurt
• C12N 1/20 - BacteriaCulture media therefor